Balyasny Asset Management
CORT icon

Balyasny Asset Management’s Corcept Therapeutics CORT Stock Holding History

Balyasny Asset Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.2M Buy
+25,349
New +$1.53M ﹤0.01% 1764
2026
Q1 		– Sell
-15,852
Closed -$552K – 2969
2025
Q4 		$552K Sell
15,852
-16,995
-52% -$1.33M ﹤0.01% 2482
2025
Q3 		$2.73M Sell
32,847
-14,498
-31% -$1.05M ﹤0.01% 1660
2025
Q2 		$3.48M Buy
47,345
+42,281
+835% +$3.07M 0.01% 1471
2025
Q1 		$578K Sell
5,064
-4,416
-47% -$269K ﹤0.01% 2222
2024
Q4 		$478K Sell
9,480
-3,515
-27% -$184K ﹤0.01% 2209
2024
Q3 		$601K Buy
+12,995
New +$462K ﹤0.01% 2192
2024
Q1 		– Sell
-6,993
Closed -$227K – 2689
2023
Q4 		$227K Buy
+6,993
New +$192K ﹤0.01% 2274
2022
Q1 		– Sell
-111,397
Closed -$2.21M – 2525
2021
Q4 		$2.21M Buy
111,397
+67,619
+154% +$1.37M 0.01% 1170
2021
Q3 		$862K Buy
+43,778
New +$916K ﹤0.01% 1375
2020
Q1 		– Sell
-53,736
Closed -$650K – 1207
2019
Q4 		$650K Buy
53,736
+30,091
+127% +$419K ﹤0.01% 966
2019
Q3 		$334K Sell
23,645
-49,380
-68% -$607K ﹤0.01% 1005
2019
Q2 		$814K Buy
+73,025
New +$814K 0.01% 1132
2018
Q2 		– Sell
-33,263
Closed -$547K – 1825
2018
Q1 		$547K Buy
+33,263
New +$616K ﹤0.01% 1412
2017
Q1 		– Sell
-11,704
Closed -$85K – 1614
2016
Q4 		$85K Sell
11,704
-1,198
-9% -$9.39K ﹤0.01% 1322
2016
Q3 		$84K Buy
+12,902
New +$75K ﹤0.01% 931
2016
Q2 		– Sell
-39,140
Closed -$183K – 1201
2016
Q1 		$183K Buy
+39,140
New +$152K ﹤0.01% 1142

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Balyasny Asset Management's CORT Position: Q2 2026 in Review

Balyasny Asset Management opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 25,349 shares worth $2.2M. The stake represents ﹤0.01% of the portfolio and ranks #1764 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in CORT as recently as Q4 2025.

Balyasny Asset Management first reported a position in CORT in Q1 2016 and has held it in 17 quarters since. The position peaked at $3.48M in Q2 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Balyasny Asset Management held 25,349 shares of Corcept Therapeutics worth $2.2M as of Q2 2026.
  • Corcept Therapeutics was a new Balyasny Asset Management position in Q2 2026.
  • Corcept Therapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #1764 holding.
  • Balyasny Asset Management first reported a position in Corcept Therapeutics in Q1 2016 and has held it in 17 quarters since.
  • Balyasny Asset Management's Corcept Therapeutics position peaked at $3.48M in Q2 2025.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.